Government Support for Anxiety Disorder will Continue Steering the North American Schizophrenia Drugs Market

Published: Sep 2020

North American schizophrenia drugs market is projected to grow at a significant CAGR of 2.1% during the forecast period (2020-2026). The increasing incidence of anxiety disorders in North America is generating the demand for different types of medication and therapies for its treatment and thereby is expected to propel the growth of the schizophrenia drugs market in the region. The incorporation of anti-stress programs including yoga, therapy, Employee Assistance Program (EAPs), social activities, childcare initiatives, provision of work from home, flexible timings, and mindfulness training are some other factors that can make a significant contribution to the schizophrenia drugs market growth in the region.

Browse the full report description of "North American Schizophrenia Drugs Market Size, Share & Trends Analysis Report by Therapeutic Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, and Others) and by Treatment (Oral and Injectables) and Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/north-american-schizophrenia-drugs-market

In addition to the rising prevalence of major depressive disorders and anxiety disorders, the high prevalence of PTSD in the US is further supporting the growth of the schizophrenia drugs market. The National Centre for PTSD offers mobile applications (apps) including self-help, companion apps, and other apps. The different self-help apps for monitoring of PTSD include PTSD Family Coach, Mindfulness Coach, VetChange, and AIMS. The treatment companion apps offered by the National Centre for PTSD, for use with a health care provider to make treatment easier include CPT Coach, PE Coach, CBT-iCoach, ACT Coach, and Stagecoach. Other apps for monitoring of related disorders include Mood Coach, Concussion Coach, Parenting2Go, Moving Forward, and Stay Quit Coach. These apps work on both the iOS and Android devices. In addition, the National Centre for PTSD offers online programs including PTSD coach online, VetChange, community reinforcement and family training-post trauma stress disorder (CRAFT-PTSD), community reinforcement and family training-substance use disorder (CRAFT-SUD).

Market Coverage

Report Elements

Details

Study Period

2019-2026

Base year

2019

Forecast period

2020-2026

Segments Covered

By Therapeutic Class and By Treatment

Countries Covered

US and Canada

Key Companies Profiled

Allergan PLC, Catalent, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc.


Key questions addressed by the report

  • What is the market growth rate during the forecast period?
  • Which segment/region dominates the market in the base year?
  • Which segment/region will project the fastest growth in the market during the forecast period?
  • How COVID-19 will impact the market growth in 2020 and coming years?

o Recovery Timeline

o Deviation from pre-COVID-19

o Most affected region/segment

o Recommendations 

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

North American Schizophrenia Drugs Market – Segmentation

By Therapeutic Class

  • Second Generation Antipsychotics 
  • Third Generation Antipsychotics
  • Others (First Generation Antipsychotics)

By Treatment

  • Oral 
  • Injectables

North American Schizophrenia Drugs Market – Segmentation by Geography

  • United States
  • Canada
To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/north-american-schizophrenia-drugs-market